Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in refractory/relapsed autoimmune hemolytic anemia
NCT04398459Phase 2Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in autoimmune hemolytic anemia (AIHA), sponsored by Institute of Hematology and Blood Diseases Hospital. Started May 2020; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT04398459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398459.